Last reviewed · How we verify
NCT04023266: PANACEA
A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI
Phase 2 trial testing Intravenous N-Acetylcysteine in STEMI in 44 participants. Completed in 1 January 2022.
15 November 2020
Quick facts
| Lead sponsor | University of Alberta |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 20 September 2019 |
| Primary completion | 15 November 2020 |
| Estimated completion | 1 January 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Intravenous N-Acetylcysteine — full drug profile →
Conditions studied
- STEMI — all drugs for STEMI →
Sponsor
University of Alberta
Who can join
Adults 18 to 80, any sex, with STEMI. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The PANACEA trial is an investigator-initiated prospective, single-center, two-arm, non-blinded pilot randomized controlled trial of high-dose IV N-Acetylcysteine therapy used as an adjunct to pharmaco-invasive reperfusion in patients presenting early after a large STEMI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04023266
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for STEMI
Currently open trials in the same condition.
- NCT06966674 — No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track · NA · recruiting
- NCT06678074 — Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI · Phase 1, PHASE2 · active not recruiting
- NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
- NCT06528821 — AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS · active not recruiting
- NCT07026708 — TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevat · recruiting
Other University of Alberta trials
Trials by the same sponsor.
- NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
- NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
- NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
- NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
- NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04023266 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alberta
- Last refreshed: 6 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04023266.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing